General description
An anti-tumor antibiotic and a highly effective myotoxin that inhibits topoisomerase II (IC50 = 100 nM). Binds to nucleic acids, presumably by specific intercalation into the DNA double helix, inhibiting nucleic acid synthesis. Cytotoxicity seems to be due to its ability to intercalate with DNA, interact with plasma membranes, and take part in oxidation-reduction reactions. Induces apoptosis in rhabdomyosarcoma cell lines.
Antitumor antibiotic and a highly effective myotoxin that inhibits topoisomerase II (IC50 = 100 nM). Binds to nucleic acids, presumably by specific intercalation into the DNA double helix, thereby inhibiting nucleic acid synthesis. Induces apoptosis in rhabdomyosarcoma cell lines. Also available as a 10 mM solution in H2O (Cat. No. 504042
).
Doxorubicin HCl, CAS 25316-40-9, is an antitumor antibiotic that inhibits topoisomerase II (IC₅₀ = 100 nM).
包装
10 mg in Plastic ampoule
Biochem/physiol Actions
Primary Target
topoisomerase 2
Product does not compete with ATP.
Warning
Toxicity: Carcinogenic / Teratogenic (D)
Reconstitution
Following reconstitution, refrigerate (4°C). Stock solutions are stable for up to 1 month at 4°C. Under acidic conditions doxorubicin is converted to a water-insoluble adriamycinone and a water soluble reducing sugar, daunosamine.
Other Notes
A′Hern, R.P., and Gore, M.E. 1995. J. Clin. Oncol. 13, 726.
Nooter, K., et al. 1995. Br. J. Cancer 71, 556.
Noviello, E., et al. 1994. Mutat. Res.311, 21.
Anderson, R.D., et al. 1993. Mutat. Res.294, 215.
Hershko, C., et al. 1993. J. Lab. Clin. Med.122, 245.
Jongmans, W., et al. 1993. Mutat. Res.294, 207.
O′Shaughnessy, J.A., and Cowan, K.H. 1993. J. Am. Med. Assoc.270, 2089.
Theyer, G., et al. 1993. J. Urol.150, 1544.
Tritton, T.R., and Yee, G. 1982. Science217, 248.